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Pyclooxygenase-1 Mediates the
inal Stage of Morphine-Induced Delayed
ardioprotection in Concert With Cyclooxygenase-2
iaojing Jiang, MD,* Enyi Shi, MD, PHD,† Yoshiki Nakajima, MD, PHD,* Shigehito Sato, MD,*
oji Ohno, PHD,‡ Hui Yue, MD*
amamatsu, Japan
OBJECTIVES We sought to investigate the time course of morphine-induced delayed cardioprotection and
examine the role of cyclooxygenase (COX) in this cardioprotective effect.
BACKGROUND Cyclooxygenase-2 has been shown to be essential for the delayed cardioprotection induced by
ischemic preconditioning and delta-opioid agonists.
METHODS Male mice were subjected to 45 min of coronary artery occlusion followed by 120 min of
reperfusion. Expressions of COX-2 and COX-1 were assessed by Western blotting, and the
myocardial prostaglandin (PG)E2 and 6-keto-PGF1-alpha contents were measured using
enzyme immunoassays.
RESULTS A powerful infarct-sparing effect appeared 24 and 48 h after morphine preconditioning and
faded after 72 h. After 24 h, the anti-infarct effect was associated with enhanced myocardial
levels of COX-2, PGE2, and 6-keto-PGF1-alpha, and no changes in COX-1 protein levels
were found. Cardioprotection and increases in PGE2 and 6-keto-PGF1-alpha were completely
abolished by the COX-2–selective inhibitor NS-398 and the non-selective COX inhibitor
indomethacin, whereas the COX-1–selective inhibitor SC-560 had no effect. After 48 h,
up-regulation of myocardial PGE2 and 6-keto-PGF1-alpha was also observed, and COX-1
expression was enhanced markedly, but only a slight increase in COX-2 expression was
apparent. Cardioprotection and the increases in PGE2 and 6-keto-PGF1-alpha 48 h after
morphine administration were abrogated only by indomethacin, and not by SC-560 or
NS-398.
CONCLUSIONS Morphine confers delayed cardioprotection via a COX-dependent pathway; COX-2 is
essential for the cardioprotection observed in the initial stage (24 h), whereas, in the final
stage (48 h), cardioprotection is mediated by COX-1 in concert with COX-2. (J Am Coll
























dschemic preconditioning confers biphasic cardioprotection:
he acute phase is limited to 1 to 3 h after a brief ischemic
timulus (1), and the delayed phase emerges 24 h later and
ay last up to 72 h (2,3). The biphasic cardioprotective
ffects of ischemic preconditioning are also mimicked by
pioids (4–6), and delayed cardioprotection induced by a
elta1-opioid receptor agonist has been reported to persist
or up to 48 h after preconditioning (7). Morphine, the most
idely used opioid, has been shown to induce the acute
hase of cardioprotection in a variety of studies (4,8,9).
urthermore, our laboratory recently demonstrated that
orphine can also produce delayed cardioprotection in mice
4 h after administration (10). However, the duration of
orphine-induced delayed cardioprotection is still
nknown.
Delayed ischemic preconditioning has been shown to be
complex process that involves a network of intricate
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005, accepted February 1, 2005.egulatory mechanisms at the levels of cell signaling and
ene expression. Convincing evidence indicates that cyclo-
xygenase (COX)-2 mediates the delayed cardioprotection
nduced by ischemic preconditioning in rabbits (3,11,12)
nd mice (13,14) through enhanced production of cytopro-
ective prostanoids such as prostaglandin (PG)E2 and PGI2.
he COX-2 pathway is also essential for conferring the
elayed cardioprotection afforded by heat stress (15) and
olatile anesthetics (16), as well as by -opioid receptor
gonists (6,17,18) in rat and rabbit models. Although
ivergent stimuli confer similar cardioprotective effects in
ifferent species, the molecular regulatory mechanisms in-
olved in these effects may be different. Hence, it has been
ound that delayed cardioprotection induced by activation of
he adenosine A1 or A3 receptors is independent of COX-2
19). Cyclooxygenase-1, the other COX isoform, is consti-
utively expressed in most tissues, including heart, and has
een found to be involved in gastroprotective effects induced
y ischemic preconditioning (20,21). However, the role of
OX-1 in cardioprotection is poorly understood. Long-
erm inhibition or genetic disruption of COX-1 has been
eported to increase cardiac ischemia/reperfusion injury in
ice (22), whereas COX-1 has been found not to mediate
elayed cardioprotection induced by a delta-opioid receptor
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COX-1 Is Involved in Cardioprotection by Morphine May 17, 2005:1707–15elayed cardioprotection conferred by morphine, a non-
elective opioid agonist, has not been examined in mice.
Delayed cardioprotection persists for a substantial period
f time, but almost all studies of the cellular and molecular
echanisms of this event have been performed for about
4 h after the stimulus. In a recent report, it has been shown
hat the cardioprotection observed in the final stage (72 h)
f late ischemic preconditioning is mediated by neuronal
itric oxide synthase and not by inducible nitric oxide
ynthase, which mediates cardioprotection in the first 24 h
fter ischemic preconditioning (3). These findings suggest
hat delayed cardioprotection is not mediated through the
ame mechanism throughout its duration, and that diver-
ent mechanisms may be involved in the initial and final
tages of delayed preconditioning.
In the current study, we sought to investigate the time
ourse of morphine-induced delayed cardioprotection in a
urine model of coronary artery occlusion and reperfusion
nd determine the potential role of COX in the initial and
nal stages of this cardioprotective effect.
ETHODS
nimals. Male B6129PF2/J mice (body weight 25 to 35 g)
urchased from Jackson Laboratory (Bar Harbor, Maine)
ere used in the study. The experimental protocol was
pproved by the Ethics Review Committee for Animal
xperimentation of Hamamatsu University School of Med-
cine and was in accordance with the National Institute of
ealth’s “Guide for the Care and Use of Laboratory
nimals.”
rugs and chemicals. Morphine was purchased from
hionogi Co. (Osaka, Japan). NS-398 and indomethacin
ere obtained from Sigma Chemical (St. Louis, Missouri),
nd SC-560 was purchased from Cayman Chemical (Ann
rbor, Michigan).
urgical procedures. Myocardial ischemia was induced by
oronary artery occlusion as previously described (10). The
egion at risk was expressed as a percentage of the weight of
he left ventricle, and the infarct size was expressed as a
ercentage of the weight of the region at risk.
rotocol of studies for myocardial infarction. Mice were
ssigned to 13 groups, as shown in Figure 1. All groups were
ubjected to 45 min of coronary occlusion followed by 120
in of reperfusion. The first series of mice was used to







SC  SC-560rotection (Fig. 1A). Group I (control) received saline (0.1 al) intraperitoneally 24 h before coronary occlusion.
roups II to IV (M 24 h, M 48 h, and M 72 h) were
retreated with morphine (0.3 mg/kg) intraperitoneally
4 h, 48 h, or 72 h before induction of myocardial ischemia.
he dose of morphine used in the current study has been
eported to induce powerful cardioprotection in mice and
ats (9,10). The second series of experiments was performed
o investigate the effects of selective and non-selective COX
nhibitors on the initial stage of morphine-induced delayed
ardioprotection (Fig. 1B). Groups V to VII were used as
rug control groups: mice received the selective COX-2
nhibitor NS-398 (5 mg/kg, group V [NS]), the selective
OX-1 inhibitor SC-560 (10 mg/kg, group VI [SC]), or
he non-selective COX inhibitor indomethacin (5 mg/kg,
roup VII [IN]) intraperitoneally 30 min before coronary
cclusion. Mice in groups VIII to X were pretreated with
orphine (0.3 mg/kg) intraperitoneally 24 h before coro-
ary occlusion, and intraperitoneal injections of NS-398
5 mg/kg), SC-560 (10 mg/kg), and IN (5 mg/kg) were
dministered to group VIII (M 24 h  NS), group IX (M
4 h  SC), and group X (M 24 h  IN), respectively, 30
in before coronary occlusion. A third series of experiments
as performed to define the role of COX in the final stage
f morphine-induced delayed cardioprotection (Fig. 1C).
ice that had been pretreated with morphine (0.3 mg/kg)
8 h earlier received NS-398 (5 mg/kg; group XI: M 48 h
NS), SC-560 (10 mg/kg; group XII: M 48 h  SC), or
ndomethacin (5 mg/kg; group XIII: M 48 h  IN) 30 min
efore coronary occlusion. NS-398, SC-560, and indo-
ethacin were dissolved in 50% dimethyl sulfoxide (6). The
ose of NS-398, SC-560, and indomethacin have previously
een shown to effectively block COX-2 (6,17), COX-1
23), and COX (22) activity, respectively.
easurement of PGE2 and 6-keto-PGF1-alpha levels. In
parallel series of experiments, hearts were collected from
roups I (control), II (M 24 h), III (M 48 h), IV (M 72 h),
III (M 24 hNS), IX (M 24 h SC), X (M 24 h IN),
I (M 48 h  NS), XII (M 48 h  SC), and XIII (M 48 h
IN) (n  4 to 5 per group) (Fig. 1). Myocardial levels of
GE2 and 6-keto-PGF1-alpha (the stable metabolite of
GI2) were determined using enzyme immunoassay kits
Cayman Chemical), as previously described (11).
estern blot analysis of myocardial COX-2 and COX-1.
dditional mice from groups I (control), II (M 24 h), III
M 48 h), and IV (M 72 h) were euthanized without
oronary occlusion and reperfusion (n  5 for each group,
ig. 1). Tissue samples were homogenized in buffer A
containing 25 mmol/l Tris-HCl [pH 7.4], 0.5 mmol/l
DTA, 0.5 mmol/l EGTA, 1 mmol/l PMSF, 1 mmol/l
TT, 25 mmol/l NaF, 1 mmol/l Na3VO4, and 25 g/ml
eupeptin) and centrifuged at 1,000 g for 10 min. The
upernatant (the cytosolic fraction) was carefully removed
nd re-centrifuged at 16,000 g for 15 min to eliminate any
ontaminating pellet. The initial pellet was re-suspended in
lysis buffer (buffer A  1% Triton X-100) and incubatedt 4°C for 2 h. Samples were centrifuged at 16,000 g for 15
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COX-1 Is Involved in Cardioprotection by Morphine May 17, 2005:1707–15in. The resulting supernatants were collected as membra-
ous fractions (6,11,24). Protein extracts were separated on
% sodium dodecyl sulfate-polyacrylamide gels (100 g of
rotein per lane) and then transferred onto a nitrocellulose
embrane. Blots were blocked for 1 h at room temperature
ith 5% nonfat dry milk in Tris-buffered saline and 0.1%
ween-20 (TBS-T) and were then washed in TBS-T. The
embrane was incubated with a polyclonal rabbit antibody
gainst mouse COX-1 or COX-2 (dilution, 1:500, Santa
ruz Biotechnology, Santa Cruz, California) at 4°C over-
ight. After washing with TBS-T, the membrane was
ncubated with an antirabbit horseradish peroxidase-linked
ntibody (dilution, 1:5,000, Nacalai Tesque, Kyoto, Japan)
or 1 h. The membranes were developed using enhanced
hemiluminescence and exposed to X-ray film for an appro-
riate duration. The optical density for each band on the
estern blot was quantified using the National Institute of
ealth image program and was normalized to the corre-
ponding Ponceau stain signal. Protein content was ex-
ressed as a percentage of the corresponding protein in
ontrols (group I).
tatistics. All values are reported as mean  SEM. Dif-
erences among the groups were analyzed by a one-way or a
wo-way repeated-measures (time and group) analysis of
ariance, as appropriate, followed by unpaired Student t
ests with the Bonferroni correction. Statistical significance
as defined as p  0.05.
able 1. Reasons for Excluding Mice From the Study for Infarct
I II III IV V VI
ice instrumented 10 9 10 11 9 10
eath 2 1 2 3 1 1
echnical difficulties 1 2
oor staining 1 1
inal number 7 8 8 8 6 7








7 72.4  3.4 62.0  3.1 59.3  3.8* 436  13
I 8 69.9  3.9 63.0  2.9 60.3  3.5 446  13
II 8 76.9  4.5 66.4  4.4 62.4  4.3 418  12
V 8 66.3  4.7 64.4  3.9 58.8  4.2 444  16
6 68.2  6.0 65.0  4.9 56.7  4.8 463  22
I 7 69.8  5.6 63.7  3.6 56.0  3.8 437  23
II 7 74.3  4.4 68.6  2.2 60.9  5.1 428  22
III 8 70.5  3.6 64.1  3.0 53.9  4.0* 458  21
X 7 72.3  3.9 65.0  3.4 58.6  4.6 448  19
7 70.1  3.6 66.7  3.5 58.6  4.6 442  21
I 7 73.0  3.4 64.9  2.8 61.0  4.7 434  18
II 7 68.1  2.7 62.1  2.5 57.7  4.4 431  17
III 7 73.4  4.1 66.1  4.0 59.4  4.2 430  20alues given as mean  SEM. *p  0.05 vs. baseline.
HR  heart rate; MAP  mean arterial blood pressure; n  number of animals; RPPESULTS
ortality and exclusion. A total of 123 mice were initially
ncluded in the protocol for the infarct-size study; 29 mice
ere excluded for the reasons shown in Table 1.
emodynamics. Mean arterial blood pressure and heart
ate were recorded in all groups throughout the experimen-
al periods. The rate-pressure product (mean arterial blood
ressure  heart rate/1,000) was calculated as an index of
xygen demand. Table 2 shows the hemodynamic values
rom all 13 groups. No significant differences in these values
ere observed among the groups at any time point. Coro-
ary artery occlusion and reperfusion produced a similar
ncrease in heart rate and similar decreases in mean arterial
lood pressure and rate-pressure product in all experimental
roups.
nfarct size. The myocardial region at risk, expressed as a
ercentage of the weight of the left ventricle, did not differ
ignificantly among the 13 experimental groups (Fig. 2).
igure 3 summarizes the infarct size expressed as a percent-
ge of the region at risk for each group. Infarct size was
ignificantly smaller in mice preconditioned with morphine
4 h before induction of myocardial ischemia (group II)
han in control mice (21.4  2.2% vs. 43.3  3.5% of the
egion at risk, p  0.001). A similar anti-infarct effect was
lso observed in the mice pretreated 48 h before myocardial
schemia (group III, 24.7  2.9% of the region at risk, p 
.003 vs. control group). However, injection of morphine
Group
TotalII VIII IX X XI XII XIII
9 8 9 8 11 10 9 123
2 2 3 2 2 21
1 1 5
1 3
7 8 7 7 7 7 7 94









67  17 480  15 31.4  1.1 28.9  1.8 28.6  2.3
55  16 476  14 30.9  1.3 28.5  1.2 28.8  2.1
40  18 464  16 31.9  1.4 29.5  2.7 28.9  2.0
52  21 481  14 29.2  1.9 29.4  2.7 28.1  1.9
68  25 495  15 31.1  1.9 30.7  3.3 28.0  2.4
56  24 487  15 30.0  1.5 29.3  2.7 27.3  2.0
49  24 481  21 31.4  1.3 30.9  2.2 29.2  2.5
65  18 497  16 32.1  1.7 29.9  2.1 26.8  2.1
72  18 501  19 32.3  1.9 30.7  2.1 29.5  2.6
68  16 487  14 31.0  2.1 31.2  1.8 28.7  2.6
84  19 495  12 31.6  1.9 31.5  1.8 30.4  2.7
63  18 469  16 29.2  0.7 28.6  0.9 27.1  2.3
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May 17, 2005:1707–15 COX-1 Is Involved in Cardioprotection by Morphine2 h before coronary occlusion did not reduce the infarct
ize (group IV, 45.9  4.3%, p  0.05 vs. control group).
he infarct-sparing effect 24 h after morphine pretreatment
as completely abolished by the COX-2 selective inhibitor
S-398 (group VIII, 47.0 2.0% of the region at risk, p
.001 vs. group II) and by the non-selective COX inhibitor
ndomethacin (group X, 47.1  2.7% of the region at risk,
 0.001 vs. group II) when the drugs were injected 30 min
efore coronary occlusion. However, administration of the
OX-1 selective inhibitor SC-560 did not block the car-
igure 2. Measurement of myocardial region at risk in all experimental grou
pen circles represent individual mice, whereas solid circles represent
N  indomethacin; M  morphine; NS  NS-398; SC  SC-560.
igure 3. Measurement of myocardial infarct size in all experimental group
epresent individual mice, whereas solid circles represent mean  SEM. IN 
C  SC-560.ioprotection of this time point (group IX, 22.0  3.8% of
he region at risk, p  0.05 vs. group II). Unexpectedly,
oth NS-398 and SC-560 failed to block the cardioprotec-
ion observed 48 h after morphine pretreatment (group XI,
6.1  3.4% of the region at risk and group XII, 27.2 
.4% of the region at risk), whereas indomethacin abolished
uch infarct-sparing effect completely (group XIII, 47.5 
.7% of the region at risk, p  0.001 vs. group III).
dministration of NS-398, SC-560, or indomethacin did
ot in itself affect the infarct size in the current model.
he region at risk is expressed as a percentage of the weight of left ventricle.
n  SEM. There was no significant difference among the 13 groups.
infarct size is expressed as a percentage of the region at risk. Open circlesps. Ts. The
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COX-1 Is Involved in Cardioprotection by Morphine May 17, 2005:1707–15yocardial content of prostanoids. Morphine precondi-
ioning resulted in robust increases in myocardial PGE2 and
-keto-PGF1-alpha levels 24 h (259  23% and 210  25%
f control, respectively, p  0.003 and p  0.008) and 48 h
ater (227  22% and 200  26% of control, respectively,
 0.039 and p  0.023), compared with control mice
Fig. 4). In contrast, neither the PGE2 nor the 6-keto-
GF1-alpha level was elevated 72 h after morphine admin-
stration; 24 h after morphine pretreatment, the increases in
GE2 and 6-keto-PGF1-alpha were completely abrogated by
dministration of NS-398 or indomethacin 30 min before
uthanasia, whereas SC-560 failed to block the increases of
GE2 and 6-keto-PGF1-alpha at this stage. Importantly,
nly administration of indomethacin, but not administra-
ion of NS-398 and SC-560, completely abolished the
ncreases in myocardial PGE2 and 6-keto-PGF1-alpha levels
8 h after morphine preconditioning.
xpression of COX-2 protein and COX-1 protein. Most
f the COX proteins were expressed in the membranous
raction, as reported previously (11,25,26). As illustrated in
igure 5A, a weak COX-2 signal was detected in control
earts. The expression of COX-2 protein increased mark-
dly 24 h after morphine administration (295  39% of
ontrol, p  0.001) (Fig. 5B), and COX-2 expression was
till higher than in control mice 48 h after morphine
dministration, although the difference was not statistically
ignificant (161  32% of control, p  0.865). No marked
hange in COX-2 expression was observed 72 h after
orphine preconditioning, compared with control mice.
Myocardial expression of COX-1 protein was present in
ontrol mice at a low level and did not change significantly
n morphine-preconditioned mice after 24 and 72 h. Sur-
risingly, significant up-regulation of COX-1 protein was
vident 48 h after morphine preconditioning (167 26% of
ontrol, p  0.023). Representative Western blots and the
ensitometric quantification of COX-1 expression are
igure 4. Myocardial content of prostaglandin (PG)E2 and 6-keto-
N  indomethacin; NS  NS-398; SC  SC-560. *p  0.05 vs. controhown in Figure 6.
e
mISCUSSION
he salient findings of the current study can be summarized
s follows: 1) morphine induces powerful cardioprotection
gainst myocardial infarction 48 h later in mice, similarly to
hat observed 24 h after morphine administration, but such
ardioprotection disappears 72 h after morphine pretreat-
ent; 2) COX-2 plays an obligatory role in mediating the
nitial stage (24 h after morphine administration) of
orphine-induced delayed cardioprotection, and the car-
ioprotective effect of this stage is independent of COX-1;
nd 3) the final stage (48 h after morphine administration)
f morphine-induced delayed cardioprotection is mediated
y COX-1 in concert with COX-2.
-alpha after morphine (M) pretreatment. Data are mean  SEM.
 0.05 vs. M 48 h; ‡p  0.05 vs. M 24 h.
igure 5. Expression of cyclooxygenase (COX)-2 in the membranous
raction of myocardium. (A) Representative Western blots illustrating
OX-2 expression. (B) Densitometric quantification of COX-2 proteinxpressed as a percentage of the average value of control mice. Data are
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May 17, 2005:1707–15 COX-1 Is Involved in Cardioprotection by Morphineime course of morphine-induced delayed cardioprotec-
ion. Delayed cardioprotection produced by delta-opioid
gonists has been described clearly in several rat models
5–7,17,18). Our laboratory has previously demonstrated
hat morphine, a -opioid receptor agonist with -opioid
eceptor properties (27), produces delayed cardioprotection
n mice (10). In the current study, myocardial infarct size as
percentage of the region at risk was significantly decreased
8 h after morphine preconditioning, as observed for a delay
f 24 h after morphine administration. The anti-infarct
ffect was lost with a 72-h delay. These data are consistent
ith the observations of Fryer et al. (7), who showed in a rat
odel that a -opioid agonist can induce delayed cardio-
rotection beginning 24 h after a single pretreatment and
ading after 72 h. However, it has also been suggested that
elayed ischemia preconditioning may last for at least 72 h
2,3,28).
ole of COX in morphine-induced delayed cardiopro-
ection. Cyclooxygenase is the rate-limiting prostanoid
ynthase, and it regulates the synthesis of prostanoids by
atalyzing the conversion of arachidonic acid to PGH2, the
ommon precursor of bioactive prostanoids (29,30). Two
istinct COX isoforms have been characterized: COX-1 is
esponsible for constitutive prostanoid formation, whereas
OX-2 is induced in response to stress, but is also consti-
utively expressed in some tissues (29,30). Accumulating
vidence has shown that COX-2 plays an essential role in
onferring delayed cardioprotection induced by divergent
athophysiological stimuli or pharmacological agents. Up-
egulation of COX-2 appears to be necessary for the
evelopment of delayed cardioprotection 24 h after an
schemic preconditioning stimulus (3,11,12,14), heat stress
igure 6. Expression of cyclooxygenase (COX)-1 in the membranous
raction of myocardium. (A) Representative Western blots showing
OX-1 expression. (B) Densitometric quantification of COX-1 protein
xpressed as a percentage of the average value of control mice. Data are
ean  SEM. M  morphine. *p  0.05 vs. control.15), and -opioid agonist administration (17). Although ether similar studies have reported no changes in the level of
OX-2 protein, these studies have shown that the late
hase of cardioprotection induced by a -opioid agonist (6)
r volatile anesthetics (16) is completely abolished by
elective inhibition of COX-2. In contrast, COX-2 does not
ontribute to the delayed cardioprotection induced by aden-
sine A1 and A3 receptor agonists (19) and by acute
ystemic hypoxia (31). In the present study, the infarct-
paring effect and the increases in myocardial PGE2 and
-keto-PGF1-alpha contents 24 h after morphine adminis-
ration were completely abolished by the COX-2 selective
nhibitor NS-398 and the nonselective COX inhibitor
ndomethacin, whereas the COX-1 selective inhibitor SC-
60 did not affect the cardioprotective effect and the
ncreases in prostanoids. Corroborating this finding, only
he expression of COX-2 protein, but not COX-1, was
ound to be up-regulated 24 h after morphine administra-
ion. These data suggest that COX-2 plays a key role in
ardioprotection 24 h after morphine preconditioning,
hile COX-1 is not involved. In line with this result, it has
een reported that COX-1 does not mediate delayed
ardioprotection 24 h after -opioid agonist precondition-
ng, whereas COX-2 was found to do so (6).
Because morphine-conferred delayed cardioprotection
asted for 48 h in our study, we also investigated the role of
OX-2 at this stage. Surprisingly, pharmacological inhibi-
ion of COX-2 or COX-1 alone failed to block the
nti-infarct effect in the final stage (48 h) after morphine
reconditioning. In contrast, cardioprotection was com-
letely abolished by the nonselective COX inhibitor indo-
ethacin. Only a slight up-regulation of COX-2 expression
as observed at this stage, but COX-1 expression was
nhanced markedly, and there were also marked increases of
GE2 and 6-keto-PGF1-alpha in the myocardium. Further-
ore, the changes of myocardial prostanoids were com-
letely blocked by administration of indomethacin, but not
y NS-398 or SC-560. These findings suggest that the
ignaling pathway responsible for morphine-induced de-
ayed cardioprotection differs in the initial (up to 24 h) and
nal stages. Hence, both COX-1 and COX-2 are involved
n the final stage of morphine-induced delayed cardiopro-
ection in mice. When COX-2 is inhibited pharmacologi-
ally, cardioprotection and the increases in PGE2 and
-keto-PGF1-alpha levels observed 48 h after morphine
dministration may be generated primarily via enhancement
f COX-1. We note that COX-1 has been shown to be
ardioprotective and to generate PGE2 and 6-keto-
GF1-alpha in COX-2 gene knockout mice (22). Although
xpression of COX-2 was not enhanced significantly 48 h
fter morphine administration, it may still be the main
ontributor to the infarct-sparing effect and the increases in
GE2 and 6-keto-PGF1-alpha when COX-1 is blocked,
articularly because COX-2 function can be enhanced
ithout an increase in expression level (6,16). In contrast to
ur results, Wang et al. (3) have shown that COX-2 is
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COX-1 Is Involved in Cardioprotection by Morphine May 17, 2005:1707–15itioning, although the initial and final stages of this process
re mediated by different mechanisms, a discrepancy that
ay be due to the different stimuli and spices used in the
wo studies.
To assess COX enzymatic activity, the myocardial levels
f PGE2 and 6-keto-PGF1-alpha (the stable metabolite of
GI2) were measured. Both PGI2 and PGE2 have been
eported to have cardioprotective properties against isch-
mia and reperfusion injury (32–35). In the current study,
yocardium PGE2 and 6-keto-PGF1-alpha levels were en-
anced significantly 24 and 48 h after morphine precondi-
ioning, and faded after 72 h, consistent with the time
ourse of morphine-induced delayed cardioprotection. Fur-
hermore, the increase of PGE2 and 6-keto-PGF1-alpha
ould be blocked by pharmacological inhibition of COX. In
greement with these findings, enhanced levels of myocar-
ial PGE2 and 6-keto-PGF1-alpha have been found to
ccompany delayed cardioprotection induced by ischemic
reconditioning (3,11,12,14) and -opioid receptor agonists
6,17). Prostaglandins are also involved in acute cardiopro-
ection conducted by ischemic preconditioning (36) and
ngiotensin II type 1-receptor antagonist (37); PGE2 and
GI2 may be mediators that activate ATP-sensitive potas-
ium (KATP) channels (38,39), which are essential for
ediation of opioid-induced cardioprotection (4,7,9,40,41).
herefore, it is plausible that morphine confers delayed
ardioprotection by enhancing the synthesis of COX-
ependent cardioprotective prostanoids, although it also
emains possible that morphine induces cardioprotective
ffects via altered expression of certain proteins that are
odulated by COX products.
onclusions. In conclusion, the present study provides
ovel insights into morphine-induced delayed cardioprotec-
ion and the underlying molecular mechanisms. Our find-
ngs demonstrate that the anti-infarct effect induced by
orphine persists 48 h after preconditioning. Cardiopro-
ection observed 24 h after morphine administration is
ssociated with and mediated by up-regulation of COX-2.
xpression of COX-1 is enhanced 48 h after morphine
reconditioning and COX-1, in concert with COX-2,
ediates cardioprotection at this stage. To our knowledge,
his is the first report in which COX-1 has been shown to
e up-regulated and involved in delayed cardioprotection.
hese findings suggest that morphine-induced delayed
ardioprotection is COX-dependent and that the molecular
echanism of cardioprotection differs 24 h and 48 h after
orphine preconditioning. Our observations also expand
he understanding of the cardioprotective properties of
OX-1.
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